| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$178 |
Notification regarding unquoted securities - AVH
|
29 Aug 2024 9:33AM |
$2.660 |
$1.345 |
fallen by
49.44%
|
|
| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$466 |
FY24 Corporate Governance Statement and Appendix 4G
|
29 Aug 2024 9:33AM |
$0.840 |
$1.615 |
risen by
92.26%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$534 |
Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$13.900 |
$10.650 |
fallen by
23.38%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,492 |
ASX Release - Correction Letter
|
29 Aug 2024 9:33AM |
$20.640 |
$21.730 |
risen by
5.28%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Perpetual Limited reported an underlying profit after tax (UPAT) for FY24 of A$206.1 million, up 26% on FY23.
- The total Assets Under Management (AUM) increased to A$215 billion.
- A final dividend of A$0.53 per share, 50% franked, was declared.
- Estimated cash proceeds for shareholders from the Scheme with KKR range between A$8.38 - A$9.82 per share.
- A simplification program aims to deliver annualised cost reductions of between A$25 million and A$35 million before tax, over two years.
- Orderly Board changes announced in anticipation of the completion of the transaction with KKR.
- Appointment of Bernard Reilly as CEO and Managing Director, succeeding Rob Adams.
- Perpetual's Wealth Management and Corporate Trust segments showed growth with respective UPBT increases of 15% and 4%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Appendix 4E and FY24 Annual Report
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BlueBet Holdings Ltd completed a transformational merger with betr, creating a leading Australian wagering operator.
- The company has exited the US market to focus on expanding its core Australian operations.
- Revenue increased by 19.8% to $59.5 million for the year ended 30 June 2024.
- The company reported a loss of $46.9 million, up 149.1% from the previous year.
- No dividends were paid or declared during the financial year.
- The merger with betr is expected to deliver $14 million in annualized cost savings.
- Active customers increased to 70,456, up 7.7% from the previous year.
- The company achieved its first full-year EBITDA positive result since IPO with an EBITDA of $3.3 million for its Australian operations.
- The company has implemented new compliance measures, including banning credit cards and integrating the National Self Exclusion Register.
- The strategic focus is now on growing market share in the Australian market and leveraging technology and product enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$534 |
Appendix 4G
|
29 Aug 2024 9:32AM |
$13.900 |
$10.650 |
fallen by
23.38%
|
|
| Duxton Farms Ltd (DBF) ORDINARY FULLY PAID |
Consumer Staple |
$45 |
Update - Notification of buy-back - DBF
|
29 Aug 2024 9:32AM |
$1.595 |
$0.985 |
fallen by
38.24%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$534 |
Investor Presentation
|
29 Aug 2024 9:32AM |
$13.900 |
$10.650 |
fallen by
23.38%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLINUVEL Pharmaceuticals Limited is focused on melanocortin-based pharmaceuticals for skin and brain conditions.
- The clinical pipeline includes treatments for various conditions such as xeroderma pigmentosum (XP), infantile spasms (IS), multiple sclerosis (MS), and central nervous system (CNS) disorders.
- SCENESSE® (afamelanotide 16 mg) is used in the treatment of erythropoietic protoporphyria (EPP) and is being trialed for other conditions like variegate porphyria, adolescent and adult XP, and vitiligo.
- NEURACTHEL® is being developed for instant and modified release forms to treat IS, MS, and CNS disorders.
- The company aims to build a diversified pharmaceutical group with multiple products and conditions treated, focusing on research and development, in-house manufacturing, and disciplined capital deployment.
- Financial performance includes maintaining cash reserves and disciplined capital investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Accent Group Limited (AX1) ORDINARY FULLY PAID |
Consumer Discretionary |
$854 |
Director Resignation
|
29 Aug 2024 9:32AM |
$2.030 |
$1.420 |
fallen by
30.05%
|
|
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
2024 Appendix 4E and Annual Report
|
29 Aug 2024 9:32AM |
$0.021 |
$0.019 |
fallen by
9.52%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 61% to AUD 4,086,535
- Loss from ordinary activities after tax decreased by 31% to AUD 6,847,803
- Basic and diluted earnings per share were both (1.079) cents
- No dividends were paid, recommended, or declared
- Net tangible assets per ordinary security decreased from 2.02 AUD cents to 1.25 AUD cents
- Financial statements audited with an unmodified opinion
- Annual General Meeting scheduled for on or about 15 November 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$534 |
CLINUVEL delivers increases in annual revenue, profit
|
29 Aug 2024 9:32AM |
$13.900 |
$10.650 |
fallen by
23.38%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Annual profit after income tax of $35.6 million for FY2024, a 16% increase from the previous year
- Total revenues for FY2024 reached $95.3 million, a 15% increase driven by demand for SCENESSE®
- Net profit before income tax was $50.7 million, an 11% increase
- Cash reserves increased by 17% to $183.9 million
- Seventh consecutive annual franked dividend of $0.05 per share
- CLINUVEL has achieved eight consecutive years of profitability
- The company has expended 72% of its five-year $175 million expenses plan on R&D and corporate capacity expansion
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$466 |
FY24 Full Year Results Investor Presentation
|
29 Aug 2024 9:31AM |
$0.840 |
$1.615 |
risen by
92.26%
|
|
OBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Investment income and fee revenue decreased by 10% to A$277.0m.
- Portfolio fair value increased by 11% to A$2.8bn.
- Net profit after tax before non-controlling interests increased by A$29.6m to A$30.5m.
- OBL achieved a 2.7x multiple on invested capital (MOIC) and 53% internal rate of return (IRR) for FY24.
- Fair value conversion for 34 completions reached 118% in 2H24.
- OBL successfully launched Fund 8 in 1Q24 and raised significant fund capital across 3 funds.
- Cash operating expenses (opex) were A$89.7m, below the target of A$95m.
- OBL aims for A$700 million in new commitments and A$85 million in cash opex for FY25.
- The company plans a second close for Funds 4/5 series II and launching a new fund in FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iltani Resources Limited (ILT) ORDINARY FULLY PAID |
Materials |
$14 |
ILT readies for Herberton silver-indium & antimony drilling
|
29 Aug 2024 9:31AM |
$0.255 |
$0.215 |
fallen by
15.69%
|
|
| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$466 |
FY24 Appendix 4E and Annual Report
|
29 Aug 2024 9:31AM |
$0.840 |
$1.615 |
risen by
92.26%
|
|
OBL - Price-sensitive ASX Announcement
Full Release
Key Points
- OBL achieved a net profit after tax of A$62.2 million for FY24.
- The company reported total revenue of A$185.4 million, representing an increase of 15% over the previous year.
- OBL declared a final dividend of 7 cents per share, fully franked.
- The company has a strong balance sheet with cash and cash equivalents of A$195.1 million.
- OBL continues to focus on high-value litigation finance and asset recovery services.
- The board has approved a share buyback program of up to A$50 million.
- OBL has expanded its operations in North America through the acquisition of a new litigation portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Investor Presentation
|
29 Aug 2024 9:31AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| Mac Copper Limited (MAC) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$1,528 |
2024 Half Year Results Presentation
|
29 Aug 2024 9:31AM |
$18.110 |
$18.520 |
risen by
2.26%
|
|
| Saunders International Limited (SND) ORDINARY FULLY PAID |
Industrials |
$105 |
Dividend/Distribution - SND
|
29 Aug 2024 9:30AM |
$0.820 |
$0.810 |
fallen by
1.22%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$534 |
Dividend/Distribution - CUV
|
29 Aug 2024 9:30AM |
$13.900 |
$10.650 |
fallen by
23.38%
|
|
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$33 |
Financial Results - 30 June 2024
|
29 Aug 2024 9:30AM |
$0.069 |
$0.086 |
risen by
24.64%
|
|
BTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $13.5 million, up 14% from the previous year
- Revenue margins increased to 2.9%
- Positive operating cash flow of $0.2 million for Q4 FY24
- FY24 EBITDA loss of $1.4 million and normalised loss after tax of $7.2 million
- Raised $5 million through a fully underwritten accelerated non-renounceable entitlement offer
- Closing FY24 cash was $13.3 million
- Significant cost reductions at staff, administration, and corporate levels
- Platform originations increased 35% to $145.2 million
- Outlook for FY25 includes a healthy pipeline of organic and in-organic growth opportunities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Adrad Holdings Limited (AHL) ORDINARY FULLY PAID |
Consumer Discretionary |
$57 |
Full Year FY24 Results
|
29 Aug 2024 9:29AM |
$0.675 |
$0.695 |
risen by
2.96%
|
|
AHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading Revenue of $142.9m, up 1.2% on prior corresponding period (pcp)
- Pro forma EBITDA of $18.1m, down 10.9% on pcp
- Positive cashflow from operations of $14.7m
- Final dividend of 1.61 cents per share declared, fully franked
- Total FY24 related declared dividends of 2.94cps equal to 40% of full year NPAT, fully franked
- Adrad CEO, Kevin Boyle, highlighted efficient growth driven by investments
- Customer project deferrals impacted revenue in the second half of the year
- Company to leverage growing customer base for cooling solutions in FY25
- HTS business segment to continue investing in product development for Australian and Asian markets
- Adrad Distribution to implement branch improvement initiatives for higher growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nickel Industries Limited (NIC) ORDINARY FULLY PAID |
Materials |
$3,039 |
Half Year Financial Report
|
29 Aug 2024 9:29AM |
$0.825 |
$0.700 |
fallen by
15.15%
|
|
NIC - Price-sensitive ASX Announcement
Full Release
Key Points
- Nickel Industries held an 80% interest in Hengjaya Nickel (HNI), Ranger Nickel (RNI), Angel Nickel (ANI), and Oracle Nickel (ONI) projects.
- The company's projects produced a combined 63,814 tonnes of nickel metal equivalent in the half year ended 30 June 2024.
- The Hengjaya Mine produced 6,084,127 wet metric tonnes (wmt) of nickel ore.
- Sales revenue for the group was down 9.5% to US$843.3M compared to the previous period.
- The profit after tax for the group was significantly down, totaling US$14.0M in comparison to US$49.1M in the previous period.
- Nickel Industries increased its interest in the Excelsior Nickel Cobalt HPAL Project to 44% through additional acquisitions post the half year.
- A US$250M term loan facility was executed to support funding requirements for the ENC project.
- Challenges faced included delays in licensing and above-average rainfall impacting production and costs.
- An interim dividend of A$0.025 per share was declared, funded from 100% conduit foreign income.
- The company aims for net zero emissions by 2050 and a 50% reduction in carbon intensity by 2035.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SenSen Networks Limited (SNS) ORDINARY FULLY PAID |
Information Technology |
$32 |
Appendix 4G
|
29 Aug 2024 9:29AM |
$0.035 |
$0.040 |
risen by
14.29%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
